They employed two ALL cell lines, BCR-ABL1+ SUP-B15 (CD19 + CD20−) and TMD-5 (CD19 + CD20+), to create two xenotransplant mouse models of residual leukemia for in vivo studies. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.